Isis To Speed Development Of Oral TNF-Alpha Inhibitor For Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to initiate a Phase II trial comparing oral and subcutaneous formulations of anti-TNF alpha antisense agent ISIS 104838 in mid-2005. Drug could have a chance at being the first oral TNF inhibitor on the RA market.